
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
QUANTRO Therapeutics Achieves Breakthrough in 10-Target Drug Screening
Details : Company's proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology and inflammation.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $544.0 million
Deal Type : Collaboration
QUANTRO Reaches Milestone with Boehringer in First-in-Class Cancer Treatment Development
Details : The collaboration is employing QUANTRO’s drug discovery platform based on time-resolved transcriptomics to identify drug candidates interfering with key transcriptional programs in cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $544.0 million
Deal Type : Collaboration
